Epstein Secrets

huge profits. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cut by a third or a half, there would be sufficient incentive to assume th

F.D.A. approval. Regardless of the risks, many drug companies are making huge profits. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cu

National Institute of / Neurological Disorders and Stroke iDSZ,Z;:,::S of Hc-,a;:r, ) MID National Institute on Aging 41. 1.'141 Cure AD Fund Merck Scholars Program Ellison Foundation Dana Foundation Smith Family Foundation as EFTA00799268 Agenda Dementia Discovery :.•• : Fund •.•: •

tment Management (to close in April). DDF is now seeking an additional £130M to reach its target I ttheimer's Research Department UK of Health Biogen A95tS2c. Tam de Olsuka 5 • • • • • • . a a •1 EFTA00799226 A roundabout, not a cascade :••: • Dementia • Discovery Fund • • 0

) and Tioga. He was previously on the boards of Intarcia Therapuetics (now currently a Board observer), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and

number of private investments. These have included Cerexa (NLV-I, exited in sale to Forest Labs, 5.4x multiple), Stromedix (NLV-I, exited in sale to Biogen Idec, 1.8x multiple plus milestones), Chimerix (NLV-IL, IPO - April, 2013, NASDAQ: CMRxX), and Auxilium (Sprout IX, NASDAQ: AUXL, exited at 4.6x). e